Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of June 2015, specifically reporting an immediate event dated June 21, 2015. The company is a foreign private issuer with principal executive offices in Nes Ziona, Israel. The filing details a corporate action related to its recent Initial Public Offering (IPO) on the NASDAQ Capital Market under the symbols "BVXV" and "BVXVW".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes resulting from the exercise of an underwriter's over-allotment option.
- Securities Issued: 110,000 American Depositary Shares (ADSs).
- Issuance Price: Equal to the original ADS offering price (specific dollar amount not stated in this text).
- Closing Date: June 24, 2015.
- Previous Exercise: On May 17, 2015, the underwriter previously exercised a partial option to purchase 128,000 warrants.
Material Changes Versus Prior Period
The primary material change is the increase in outstanding shares due to the partial exercise of the over-allotment option. This follows the company's IPO which closed on May 15, 2015. The total over-allotment option allowed for up to 286,500 ADSs and 286,500 warrants. This specific filing represents an additional partial exercise of 110,000 ADSs, distinct from the earlier warrant exercise.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the report does not constitute an offer to sell securities or a solicitation of an offer to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory context of the securities offering.
Key Facts for Investor Verification
- Verify the exact offering price per ADS to calculate the total capital raised from this 110,000 share issuance.
- Confirm the total number of outstanding ADSs and warrants post-closing on June 24, 2015.
- Review the full IPO prospectus (dated May 13, 2015) for the company's financial position and use of proceeds, as this 6-K does not contain financial statements.
- Note the discrepancy in the request metadata: The filing is for BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.